NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Aquestive Therapeutics, Inc. AQST
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$44.5M
▼ 22.6% vs FY2024
EPS · FY25
$-0.78
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-188.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 44.5M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 188 cents on every revenue dollar this year.
Per share
USD -0.78
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-159.5%
Net margin-188.1%
Return on assets-64.0%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−0.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.2%
−0.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+253.0%
Change, 10 years—
The share count grew 253% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 160.4M
total assets, end of FY2025
Total assetsUSD 160.4M
EquityUSD -33.7M
CashUSD 121.2M
Gross debtUSD 45.0M
Net debtUSD -76.2M
Current ratio3.14×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.1
0.1
0.0
0.1
0.0
0.1
0.1
0.1
Operating income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
Income tax $B
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−0.78
−0.51
−0.13
−1.12
−1.85
−1.66
−2.61
−2.96
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
−3347.4
·
·
Shares out B
0.12
0.09
0.07
0.05
0.04
0.03
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed